Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women

Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women: a Pilot Study

This is a prospective, observational, open-label, pharmacokinetic study will evaluate PK of SOF/DAC in lactating HCV-infected females at weaning or women who voluntarily decided to forego breastfeeding to initiate HCV infection treatment. Therefore, drug concentrations can be determined in maternal plasma and milk without risk to the children. HCV infected women at weaning after various durations of breastfeeding and HCV infected women who wish to initiate treatment immediately after delivery and forego breastfeeding will be recruited to start treatment under the guidance of their physician with SOF/DAC to determine M/P ratios of each of SOF, GS-331007 and DAC.

Study Overview

• Status: Recruiting
• Conditions: Hepatitis C Virus Infection
• Intervention / Treatment: Diagnostic test: Pharmacokinetic test

Detailed Description

Eligible women will be advised to arrange for initiation of treatment with their physician once they decide to stop breastfeeding. Treatment will be initiated once the women decide to wean their children and a warning will be given to abstain from any breast-feeding once treatment is started. This treatment is prescribed by the physician either the patients choose to participate in the study or not. In addition, effective contraceptive methods should be used. The treatment consists of SOF/DAC: 400 mg sofosbuvir and 60 mg daclatasvir administered with food for 12 weeks.

All recruited patients will be screened for the following data at baseline: Serum creatinine, bilirubin, albumin, AST, ALT, prothrombin time (PT), CBC, and viral load by PCR. The patient's general and demographic information (age, gender, height, and weight), comorbidities, and concurrent medications will be assessed and recorded in a specially designed patient data sheet.

The study will be conducted in the Faculty of Medicine Ain-Shams Research Institute Clinical Research Center (MASRI -CRC). After the first dose, women will be instructed to express their milk and discard it on the first two days and come to the research center on the third day for plasma and milk sampling. Patients will be instructed to take the dose on time especially the day before sampling. They will be asked to record the time of dose administration. They might be also followed up by telephone calls

• Study Type: Observational
• Enrollment (Anticipated): 10

Contacts and Locations

• Study Contact: Name: Manal H El-Sayed, MD; Phone Number: 002 01227461120; Email: manalhelsayed@yahoo.co.uk

Study Locations

• Egypt
  • Non-US
    • Cairo, Non-US, Egypt, 11566
      • Recruiting
      • Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Lactating HCV infected female patients

Description

Inclusion Criteria:

• Patient is at least 18 years of age at the day of screening.
• Confirmed HCV infection by PCR and known genotype (GT) 1, 4, 5, or 6.
• Female lactating patient, who will wean their children on starting treatment and ensure not to breastfeed after start treatment.
• Patients with an indication for SOF/DAC treatment for the treatment of chronic HCV.
• Patient is able and willing to sign the Informed Consent Form.
• Patient is able and willing to follow protocol requirements.

Exclusion Criteria:

• Need for co-treatment with ribavirin.
• HepBSAg positive test at screening.
• Treatment with rosuvastatin.
• Medicinal products that are potent P-glycoprotein (P-gp) and or CYP3A4 inducers in the intestine (rifampicin, rifabutin, St. John's wort [Hypericum perforatum], carbamazepine, phenobarbital and phenytoin).
• HIV co-infected patients using antiretroviral agents possibly interacting with SOF/DAC.
• Drugs associated with bradycardia including amiodarone.
• History of heart block.
• eGFR < 30 ml/min/1.73 m2.
• Compensated cirrhosis, based on historical data, evidence of decompensated cirrhosis by ascites, encephalopathy, or variceal hemorrhage and/or abnormal ALT/AST/INR/thrombocytes indicating cirrhosis.
• Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion except for conditions related to HCV.
• Clinically relevant low hemoglobin concentration at screening.
• Pregnancy
• Refusal to use proper contraception during treatment

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma and milk concentrations of sofosbuvir	Determination of plasma and milk concentrations of sofosbuvir and its metabolite GS-331007 in plasma and milk of HCV infected lactating women.	Time prior to first dose till 24 hours post first dose of sofosbuvir
Plasma and milk concentrations of daclatasvir	Determination of plasma and milk concentrations of daclatasvir in plasma and milk of HCV infected lactating women	Time prior to first dose till 24 hours post first dose

Collaborators and Investigators

• Sponsor: Ain Shams University
• Investigators: Principal Investigator: Manal SE El-Sayed, M.D, Ain Shams University, Faculty of medicine

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2020
• Primary Completion (Anticipated): November 1, 2023
• Study Completion (Anticipated): December 1, 2023

Study Registration Dates

• First Submitted: April 17, 2021
• First Submitted That Met QC Criteria: April 17, 2021
• First Posted (Actual): April 21, 2021

Study Record Updates

• Last Update Posted (Actual): August 23, 2022
• Last Update Submitted That Met QC Criteria: August 21, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: Pharmacokinetics; Egypt; Lactating Women; Sofosbuvir/daclatasvir
• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Hepatitis; Hepatitis C
• Other Study ID Numbers: CL 2489

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No